Stockscreener 앱 받기
0.7418
1.09%
-0.0082
Silo Pharma Inc 주식(SILO)의 최신 뉴스
Contrasting Silo Pharma (SILO) and Its Competitors - Defense World
Silo Pharma's SP-26 Implant Achieves All Endpoints In Preclinical Fibromyalgia Study - Nasdaq
EXCLUSIVE: Silo Pharma's Investigational Ketamine Implant Hits All Endpoints In Pain Study In Animal Models - AOL.com
Silo Pharma stock hits 52-week low at $0.76 amid market challenges - Investing.com Australia
SILO Pharma Achieves Milestone with Promising Preclinical Results for SP-26 | SILO Stock News - GuruFocus
Silo Pharma reports positive preclinical results for SP-26 - Investing.com
Silo Pharma Announces Positive Preclinical Results for SP-26, a Novel Extended-Release Ketamine Implant for Fibromyalgia - Nasdaq
Silo Pharma's SP-26 Ketamine Implant Meets All Endpoints In Fibromyalgia Study - marketscreener.com
Silo Pharma’s SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study - GlobeNewswire
Revolutionary Ketamine Implant Could Replace Opioids for Fibromyalgia Treatment, Study Shows - Stock Titan
A Guide To The Risks Of Investing In SILO Pharma Inc (SILO) - knoxdaily.com
The Significance of Moving Averages in SILO Pharma Inc Inc. (SILO) Price Performance - investchronicle.com
SILO Pharma Inc (SILO) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com
Balance Sheet Insights: SILO Pharma Inc (SILO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
Silo Pharma files patent for Alzheimer’s treatment - Investing.com Australia
Silo Pharma files patent for Alzheimer’s treatment By Investing.com - Investing.com India
Sarasota company applies for Alzheimer's drug patent - Business Observer
Silo Pharma Expands Intellectual Property Portfolio With Patent Application For Exclusively Licensed Alzheimer'S Drug - marketscreener.com
Silo Pharma (SILO) Files Patent for Innovative Alzheimer's Treatment | SILO Stock News - GuruFocus
Silo Pharma Files Patent Application for Alzheimer's Drug SPC-14 Targeting Novel Mechanism of Action - Nasdaq
Silo Pharma Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer’s Drug - GlobeNewswire
Groundbreaking Alzheimer's Treatment Patent: Columbia-Licensed Drug Targets Multiple Brain Pathways - Stock Titan
Silo Pharma (SILO) versus The Competition Financial Analysis - Defense World
Silo Pharma (SILO) versus Its Rivals Financial Analysis - Defense World
Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (“LSD”) to Treat Parkinson’s Disease - Psychedelic Alpha
Short Interest in Silo Pharma, Inc. (NASDAQ:SILO) Increases By 38.7% - Defense World
Silo Pharma Inc. (SILO) reports earnings - Quartz
Silo Pharma, Inc. SEC 10-K Report - TradingView
SILO Stock Price and Chart — NASDAQ:SILO - TradingView
Silo Pharma begins key study for PTSD treatment By Investing.com - Investing.com South Africa
Silo Pharma Doses First Participant In IND-Enabling GLP Study Of SPC-15 For PTSD Treatment - Nasdaq
Silo Pharma begins key study for PTSD treatment - Investing.com
Silo Pharma Achieves Key Milestone With First Dosing In IND-Enabling GLP Study For SPC-15 As A Groundbreaking PTSD Treatment - Marketscreener.com
Silo Pharma Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment - The Manila Times
Major PTSD Treatment Advance: FDA Fast-Track Path Opens for Revolutionary Drug SPC-15 - Stock Titan
Silo Pharma Unveils Strategic Initiatives and Drug Pipeline - TipRanks
Silo Pharma secures patent for stress disorder prophylactic - Investing.com
Silo Pharma secures patent for stress disorder prophylactic By Investing.com - Investing.com UK
Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment - Marketscreener.com
MarketsMedicine Hat News - Financial Content
Silo Pharma Granted US Patent for Intranasal Post-Traumatic Stress Disorder Treatment - Marketscreener.com
Silo Pharma, Inc. Receives Issuance Notification for Patent Related to SPC-15 Treatment for PTSD - Nasdaq
Silo Files Provisional Patent For SPC-15 Combination Treatment To Target Stress-Induced Disorders - Nasdaq
Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment - The Manila Times
Silo Pharma Expands Intellectual Property Portfolio with - GlobeNewswire
Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for ... - The Bakersfield Californian
Revolutionary Mental Health Treatment Patent: Silo Pharma's Dual-Action SPC-15 Shows Promising Results - StockTitan
Silo Pharma reports positive early data on pain treatment implant By Investing.com - Investing.com Nigeria
Silo Pharma Announces Positive Initial Pharmacokinetic, - GlobeNewswire
Silo Pharma reports positive early data on pain treatment implant - Investing.com
SILO’s valuation metrics: A comprehensive analysis - US Post News
Silo Pharma's SP-26 Shows Promising Initial Safety And Absorption Data For Pain Relief - Nasdaq
Silo Pharma Reports Positive Safety Update from SP-26 Ketamine Implant Study with No Serious Side Effects Observed - Nasdaq
Silo Pharma Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 - The Bakersfield Californian
Revolutionary Pain Treatment: SILO's Ketamine Implant Aces Initial Safety Tests - StockTitan
0.39%
3.66%
자본화:
|
볼륨(24시간):